Specifically, Balversa is approved to treat patients whose cancer has susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations and who have progressed after at least one line of systemic therapy
Gina: Yeah, this is going to be a space to watch
Existing preclinical studies in animal models have shown promising results with ferroptosis inhibitors, iron chelation, and microbiota-based therapies such as probiotics, dietary interventions, and fecal microbiota transplantation (FMT)
Mice were placed into a stereotaxic frame and a craniotomy was performed to allow unilateral microinjection of 5 l of 30 M into the left lateral ventricle (coordinates: +1 mm M/L, 0.5 mm A/P, 2.5 mm D/V from bregma)
FIB-4 incorporates routinely available clinical data and can be automated within electronic health records, enabling efficient risk stratification
This is a real, non-trivial risk that commodity pages omit entirely